AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
12.61
-0.03 (-0.20%)
At close: Oct 13, 2026, 4:00 PM EDT
12.64
+0.03 (0.25%)
After-hours: Oct 13, 2026, 7:44 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $16.82. The average 1-year stock price forecast is 33.39% higher than the current stock price, while the lowest is $9.00 (-28.63%) and the highest is $30 (+137.91%).
Price Target: $16.82 (+33.39%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 8 | 9 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 1 | 1 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Initiates $17 | Buy | Initiates | $17 | +34.81% | Sep 29, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $13 → $25 | Buy | Reiterates | $13 → $25 | +98.26% | Sep 27, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $13 | Hold | Initiates | $13 | +3.09% | Sep 24, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $30 | Buy | Reiterates | $30 | +137.91% | Sep 2, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $15 | Buy | Maintains | $15 | +18.95% | Aug 18, 2026 |
Financial Forecast
Revenue This Year
26.37M
from 75.13M
Decreased by -64.90%
Revenue Next Year
28.24M
from 26.37M
Increased by 7.12%
EPS This Year
-0.67
from -0.49
EPS Next Year
-0.76
from -0.67
EPS and Forward PE are based on non-GAAP adjusted numbers.